Stockreport

Tolero Pharmaceuticals Presents Preliminary Findings from Phase 1 Study Evaluating Investigational Agent TP-0903 in Patients with Advanced Solid Tumors at ESMO 2019

SUMITOMO CHEM UNSP/ADR  (SOMMY) 
NASDAQ:AMEX Investor Relations: sumitomo-chem.co.jp/english/ir
PDF SALT LAKE CITY, Sept. 28, 2019 /PRNewswire/ -- Tolero Pharmaceuticals, Inc., a clinical-stage company focused on developing novel therapeutics for hematological and onco [Read more]